| Name | Title | Contact Details |
|---|
Biorasi is an award-winning full service, global Clinical Research Optimized (CRO). From project design to execution success, optimization is engrained in ProAct+. An integrated platform of high performance systems, tools, and processes. By developing and implementing groundbreaking methods of optimizing clinical research, we contribute to enhancement of health and well-being for people around the world. Powered by ProAct+, Biorasi`s full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional operations around the world.
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer-oriented API manufacturer. We have a legacy of over three decades and trace our origins to the API expertise of Strides Shasun Ltd. and the technical knowhow of human API business from Sequent Scientific Ltd. We are poised to bridge the industry gap by delivering value-based products while maintaining focus on customer needs. We have 140+ scientists working at our two R&D Centers and 4 API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson`s, Alzheimer`s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.